

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Silver State Scripts Board

Draft Meeting Minutes

Date of Meeting: Thursday, March 24, 2022, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes																														
Closed Executive Session																																
Financial Review of Drug Classes with Proposed Changes	<p>Chairman Decerbo called the meeting to order at 1:14 PM on March 24, 2022.</p> <p>Roll was taken by Chairman Decerbo.</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Present</th> <th style="width: 15%; text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>The DHCFP Staff Present were as follows:</p> <p>Capurro, Antonina, Deputy Administrator</p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p> <p>Flowers, Ellen, Program Officer I</p> <p>Lither, Gabriel, Senior Deputy Attorney General (SDAG)</p>
	Present	Absent																														
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

Agenda Item	Record	Notes
	<p>A quorum was present.</p> <p>Chairman Decerbo directed Kevin Whittington to proceed with the Financial Review of Drug classes with proposed changes up for review during the First Quarter 2022 Silver State Scripts Board meeting.</p> <p>Mr. Whittington reminded the board members the financial material presented is confidential and should not be discussed or disclosed outside of this closed session of the Silver States Scripts Board meeting.</p> <p>Mr. Whittington presented the Financial Review of the Dermatological Agents – Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products class, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Neurological Agents – Antiparkinsonian Agents – Non-Ergot Dopamine Agonists class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Psychotropic Agents – ADHD Agents class, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Ophthalmic Agents – Ophthalmic Antihistamines class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Biologic Response Modifiers – Multiple Sclerosis Agents, oral class, noting the products with proposed changes in PDL status.</p>	<p>Gainwell Technology Staff Present were as follows: Leid, Giovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: Whittington, Kevin, R.Ph. LeCheminant, Jill, Pharm.D Chien, Michael, Pharm.D. Kiriakopoulos, Amanda, Pharm.D. Piccirilli, Annette Medina, Daniel</p>
Open Public Meeting		
1. Call to Order and Roll Call	<p>Chairman Decerbo called the meeting to order at 1:40 PM on March 24, 2022.</p> <p>Roll was taken by Chairman Decerbo.</p>	<p>The DHCFP Staff Present were as follows: Capurro, Antonina, Deputy Administrator</p>

Agenda Item	Record		Notes																				
		<table border="0"> <thead> <tr> <th data-bbox="1171 228 1297 266">Present</th> <th data-bbox="1297 228 1562 266">Absent</th> </tr> </thead> <tbody> <tr> <td data-bbox="1171 266 1297 310">☒</td> <td data-bbox="1297 266 1562 310">☐</td> </tr> <tr> <td data-bbox="1171 310 1297 354">☒</td> <td data-bbox="1297 310 1562 354">☐</td> </tr> <tr> <td data-bbox="1171 354 1297 397">☒</td> <td data-bbox="1297 354 1562 397">☐</td> </tr> <tr> <td data-bbox="1171 397 1297 441">☒</td> <td data-bbox="1297 397 1562 441">☐</td> </tr> <tr> <td data-bbox="1171 441 1297 485">☒</td> <td data-bbox="1297 441 1562 485">☐</td> </tr> <tr> <td data-bbox="1171 485 1297 529">☒</td> <td data-bbox="1297 485 1562 529">☐</td> </tr> <tr> <td data-bbox="1171 529 1297 573">☒</td> <td data-bbox="1297 529 1562 573">☐</td> </tr> <tr> <td data-bbox="1171 573 1297 617">☐</td> <td data-bbox="1297 573 1562 617">☒</td> </tr> <tr> <td data-bbox="1171 617 1297 660">☒</td> <td data-bbox="1297 617 1562 660">☐</td> </tr> </tbody> </table> <p data-bbox="636 678 945 716">A quorum was present.</p>	Present	Absent	☒	☐	☒	☐	☒	☐	☒	☐	☒	☐	☒	☐	☒	☐	☐	☒	☒	☐	<p data-bbox="1562 228 1963 298">Olsen, David, Social Services Chief III</p> <p data-bbox="1562 298 1963 368">Gudino, Antonio, Social Services Program Specialist III</p> <p data-bbox="1562 368 1963 438">Flowers, Ellen, Program Officer I</p> <p data-bbox="1562 438 1963 508">Lither, Gabriel, SDAG</p> <p data-bbox="1562 508 1963 578">Berntson, Kindra, Social Services Program Specialist II</p> <p data-bbox="1562 578 1963 615">Gainwell Technology Staff</p> <p data-bbox="1562 615 1963 652">Present were as follows:</p> <p data-bbox="1562 652 1963 690">Leid, Jovanna, Pharm.D.</p> <p data-bbox="1562 727 1963 797">OptumRx Staff Present were as follows:</p> <p data-bbox="1562 797 1963 834">LeCheminant, Jill, Pharm.D.</p> <p data-bbox="1562 834 1963 904">Kiriakopoulos, Amanda, Pharm.D.</p> <p data-bbox="1562 904 1963 941">Whittington, Kevin, R.Ph.</p> <p data-bbox="1562 941 1963 979">Piccirilli, Annette</p> <p data-bbox="1562 979 1963 1016">Medina, Daniel</p> <p data-bbox="1562 1016 1963 1053">Chien, Michael, Pharm.D.</p> <p data-bbox="1562 1091 1963 1161">The public attendee list is included as Attachment A.</p> <p data-bbox="1562 1198 1963 1359">Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the accuracy of the attendee list is not assured.</p>
Present	Absent																						
☒	☐																						
☒	☐																						
☒	☐																						
☒	☐																						
☒	☐																						
☒	☐																						
☒	☐																						
☐	☒																						
☒	☐																						

Agenda Item	Record	Notes
2. Public Comment on Any Matter on the Agenda.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>	
3. Administrative		
a. For Possible Action: Review and Approve Meeting Minutes from December 9, 2021.	<p>Board Member Khurana corrected the date on the posted slides. Meeting minutes reflected the correct date.</p> <p>The minutes were approved by unanimous consent.</p>	
b. Status Update by the DHCFP.	<p>Chief David Olsen discussed the start date of July 1, 2022, for Magellan Medicaid Administration as Nevada's new Pharmacy Benefit Manager (PBM). He introduced Dr. Tina Hawkins and Dr. James Kim with Magellan. He noted that Dr. Kim would be the new account director with Magellan.</p> <p>Chief Olsen discussed the public hearing to be held on March 29, 2022, at 10:00 AM regarding the Medicaid Pooling Initiative. Chief Olsen mentioned Senate Bill 325, which enables pharmacists to prescribe HIV preventative therapy and dispense oral contraceptive therapy without a prescription. He noted this rule does require certain continuing education (CE) training for pharmacists. Chief Olsen stated that provider enrollment was not expected to begin until June 2022.</p> <p>Chief Olsen introduced two new members to the Board, Elizabeth Gonzalez and Isabella Niezborala. With the introduction of new members, Chief Olsen reminded the Board of the Board's role and the bylaws regarding maintaining the PDL. He stated that the Board reviews efficacy, safety, and outcomes of drug therapy. If all of these are considered equal, then cost is considered.</p>	

Agenda Item	Record	Notes												
	Antonio Gudino reminded the Board to remain on camera during the meeting and when voting. He asked public members to stay off camera unless speaking during public comment.													
4. Established Drug Classes Being Reviewed Due to the Release of New Drugs														
a. For Possible Action: Discussion and possible adoption of Dermatological Agents – Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products.														
i. Public comment.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was offered.													
ii. Drug class review presentation by OptumRx.	Dr. Jill LeCheminant discussed Winlevi, the new product within this drug class. She presented the generic availability within the drug class and noted the indication, mechanism of action, and efficacy studies. Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent. Board Member Khurana seconded the motion. A vote was held: <table data-bbox="661 1279 1501 1388"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

Agenda Item	Record	Notes																																				
	<table border="0"> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended adding Winlevi to non-preferred on the PDL. She recommended moving Aczone to non-preferred, and Benzaclin to preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the proposed changes.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
b. For Possible Action: Discussion and possible adoption of Neurological Agents – Antiparkinsonian Agents – Non-Ergot Dopamine Agonists																																						

Agenda Item	Record	Notes																																				
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Brian Wensel with Sunovion Pharmaceuticals regarding Kynmobi. He provided information regarding Parkinson’s treatments, Kynmobi’s indication, available formulations, dosing, clinical efficacy data, and adverse events. He asked that Kynmobi be added to preferred.</p>																																					
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed the two apomorphine products, Kynmobi and Apokyn, and provided the current generic availability She noted the indication of off-episodes, clinical trial information, current guideline recommendations, and available formulations. She stated that Apokyn requires first dose administration by a medical professional.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the list is clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 1024 1503 1388"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

Agenda Item	Record	Notes																																				
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended the Board add Apokyn and Kynmobi to non-preferred. She recommended moving Mirapex ER to preferred and pramipexole ER to non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Chairman Decerbo inquired if any of the agents in this class had prior authorization criteria. Dr. LeCheminant stated that they currently did not. She noted that management occurred through preference status on the PDL. Board Member Ward asked if the DUR Board would address prior authorization criteria for the apomorphine agents if maintained as non-preferred. Board Member Khurana agreed that criteria for appropriate use might be warranted. Chairman Decerbo commented that criteria could ensure the drugs were used in the correct patients. Even though utilization was currently low, he would want it to be managed appropriately.</p> <p>Chairman Decerbo moved to accept the proposed updates as presented with the added recommendation to have the DUR Board assess prior authorization criteria for the apomorphine agents.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 987 1503 1354"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
c. For Possible Action: Discussion and possible																																						

Agenda Item	Record	Notes												
<p>adoption of Psychotropic Agents – ADHD Agents</p>														
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Lance Lewis, in Field Medical Affairs with Corium regarding Azstarys. He noted the unique characteristics of Azstarys, indication, dosage forms, dosing, and administration. He commented that Azstarys is a Schedule II product that has an early onset of action with extended duration. He provided clinical efficacy studies and safety information. He noted that complete prescribing information could be found in the package insert.</p> <p>Comment was provided by Patrick Harvey from Supernus for Qelbree. He informed the board he was available for any questions. No questions were asked.</p> <p>Dr. LeCheminant stated that a written comment was provided to the Board for Qelbree.</p>													
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. LeCheminant discussed Azstarys clinical efficacy information and dosing. She noted multiple generic formulations available in the class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>													
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1312 1501 1425"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

Agenda Item	Record	Notes																																				
	<table border="0"> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended Azstarys to be added to the PDL as non-preferred and Desoxyn to move to non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Adashek seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
5. Established Drug Classes Being Reviewed Due to the Release of New Generics																																						
a. For Possible Action: Discussion and possible																																						

Agenda Item	Record	Notes																																				
adoption of Ophthalmic Agents – Ophthalmic Antihistamines																																						
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																																					
ii. Drug class review presentation by OptumRx.	<p>Dr. LeCheminant discussed available generics.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Adashek seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 850 1503 1214"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended adding bepotastine as non-preferred.																																					

Agenda Item	Record	Notes																																				
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="659 418 1514 789"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>6. Established Drug Classes</p>																																						
<p>a. For Possible Action: Discussion and possible adoption of Biologic Response Modifiers – Multiple Sclerosis Agents, oral</p>																																						
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by KayOnda Bayo from Bristol Myers Squibb regarding Zeposia. She noted indications, clinical studies, and adverse events of Zeposia. She requested that Zeposia be moved to preferred on the PDL.</p> <p>Comment was provided by Melissa Sommers from Novartis regarding Mayzent. She stated that Mayzent was the only agent to have efficacy in</p>																																					

Agenda Item	Record	Notes																																				
	clinical trials for secondary progressive multiple sclerosis. She asked that Mayzent be moved to preferred on the PDL.																																					
ii. Drug class review presentation by OptumRx.	Dr. LeCheminant discussed available generics. Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board member Adashek moved to accept the class as clinically and therapeutically equivalent. Board Member Ward seconded the motion. A vote was held: <table data-bbox="653 667 1503 1036"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. LeCheminant recommended dimethyl fumarate move to preferred on the PDL and Tecfidera move to non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Ward moved to accept the recommendation. Board Member Adashek seconded the motion. A vote was held:																																					

Agenda Item	Record	Notes																																				
	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Gonzalez, Elizabeth, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Niezborala, Isabella, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Gonzalez, Elizabeth, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Niezborala, Isabella, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
7. OptumRx Reports: New Drugs to Market and New Line Extensions	Dr. LeCheminant reviewed dextromethorphan/bupropion, bimekizumab, tapinarof, and tirzepatide.																																					
8. Closing Discussion																																						
a. Public comments on any subject.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Dana Trippi, a Board-Certified Physician that specializes in the treatment of obesity. Dr. Trippi discussed the treatment of obesity and the need for medication therapy. She commented that she needs all the tools available to be able to treat her patients effectively. She requested that agents used in the treatment of obesity be covered. Dr. Trippi commented that other states are covering obesity agents.</p> <p>Chairman Decerbo thanked Dr. Trippi for her feedback and noted that he had received this feedback in the past. He inquired why these agents were not currently covered. Dr. LeCheminant stated that they are excluded in Chapter 1200 and that further discussion with DHCFP would need to take place prior to review. Chief Olsen said that it would be reviewed internally and that a fiscal impact would likely need to be reviewed. Board Member Khurana expressed the need of treatment for obesity and metabolic disease. Board Member Ward asked if the Board should make a motion to have these items reviewed. Gabriel Lither, SDAG, stated that this was out of</p>																																					


	the Board's purview and that the Office would review. Chief Olsen committed to review.	
b. Date and location of the next meeting.	Chairman Decerbo confirmed that the next meeting is scheduled for June 23, 2022, at the Hampton Inn Tropicana.	
c. Adjournment.	Chairman Decerbo adjourned the meeting at 2:44 PM.	


Attachment A – Members of the Public in Attendance

Ashton, Elisa, JNJ
Asokan, Vimal, Anthem
Bala, Kayson, Biogen
Balen, Valerie, Belz & Case
Bayo, KayOnda, BMS
Block, David, Corium
Bogard, Lisa, Anthem
Bott, Jason, Lily
Capen, Maribeth, Anthem
Colabianchi, Jeana
Cowan, Sarah, NV Health
Delgado, Jonathan, Novo Nordisk
Diebes, Tressa, Takeda
Eletreby, Iman, Anthem
Germain, Joe, Biogen
Patrick, Harvey, Supernus
Hawkins, Tina, Magellan
Henry, Lawrence, Fidelis
Hertzberg, Susan, Gene
Kim, James, Magellan
Levin, Amy, Anthem

Lawrence, Henry, Fidelis
Lewis, Lance, Corium
Lim, Luke, Anthem
McKenna, Brian, Oyster Point
Mendez, Natasha, BMS
Miller, Temyka, Anthem
Nguyen, Bao, JNJ
Ou, Karen, Gilead
Overman, Julia, Corium
Roa, Ryan, Merck
Santarone, Christopher, BMS
Sebastian, Paul, Optum
Selm-Keck, Emma, DK Pierce
Sommers, Melissa, Novartis
Tran, Jimmy, Molina
Trippi, Dr. Dana
Walter, Lindsey, Novartis
Wensel, Brian, Sunvion
White, Rianna, Fidelis
William, Paul
Zagrob, Michael

Attachment B – Submitted Written Comment

 Qelbree_1 pager Nevada Medicaid Testimony

 Secuado_Medicaid_Summary